Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clinton Transition Co-Chair Tanden Offers Themes For A Drug Pricing Bill In 2017

Executive Summary

FAIR Drug Pricing Act, CAP proposal and Collins bill include viable legislative movers for next administration. CMS Acting Administrator Slavitt signals that Part B demo will move forward based on CBO score.

You may also be interested in...



‘March In’ Plan Unveiled By Democratic Think Tank: A Battle Biopharma Would Welcome?

In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.

Biopharma Goes 3 For 3 In Presidential Debates

The Presidential debates are over, and the biopharmaceutical industry has to be counted among the winners, simply because there was no substantive discussion of high drug prices as an issue. That may not mean much come 2017 – but at least the industry’s reputation hasn’t been further damaged during the highest profile phase of the national campaign.

Part B Demo Could Save $2.2 Bil., CBO Says; Blocking It Would Cost Less

CMS’ proposal to test alternate payment methods for Part B drugs could save as much as $2.2 billion over 10 years, the Congressional Budget Office told Congress. However, a bill to block implementation of the program would only cost $395 million for scoring purposes.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS119314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel